NCM · Medical - Diagnostics & Research

BIAF (BIAF) Stock

$0.63 -2.64% NCM: BIAF Healthcare

Valuation

MetricValue
Price$0.63
Market Cap$2.84M
P/E Ratio-0.19
P/B Ratio1.05
P/S Ratio1.30
EPS (TTM)$0.00
52-Week High$13.80
52-Week Low$0.63
Dividend Yield0.00%

Financials & Margins

MetricValue
ROE-214.29%
ROA-136.36%
ROCE-157.14%
Gross Margin-183.33%
Operating Margin-183.33%
Net Margin-2.81%
Debt/Equity0.38
Current Ratio2.67

Annual Financials (USD)

Metric20212022202320242025
Revenue$0$0$3.0M$9.0M$6.0M
Operating Profit$-2.0M$-4.0M$-8.0M$-9.0M$-11.0M
Net Profit$-6.0M$-8.0M$-8.0M$-9.0M$-15.0M
EPS$-69.57$-54.30$-27.30$-22.50$-8.66
Op Margin—-83511.5%-314.9%-95.6%-171.6%

Balance Sheet (USD)

Metric20212022202320242025
Total Assets$1.0M$12.0M$8.0M$7.0M$11.0M
Total Liabilities$17.0M$1.0M$3.0M$4.0M$4.0M
Cash$1.0M$11.0M$3.0M$1.0M$6.0M
Borrowings$11.0M$0$2.0M$2.0M$1.0M

Latest News

bioAffinity Technologies and Pictor®, Inc. Partner to Develop and Commercialize bioAffinity’s Diagnostics for Asthma and COPD Business Wire · Jul 22, 2026 BIAF Stock Plunges 77% in 3 Months: Should You Still Hold or Sell? Zacks · Jul 9, 2026 bioAffinity Technologies’ Quarterly CyPath® Lung Sales Double to New Record as Commercial Momentum Continues Business Wire · Jul 7, 2026 Q2 Virtual Investor Summit Presentations Now Available On Demand ACCESS Newswire · Jun 30, 2026 Q2 Investor Summit Virtual Live Wednesday June 24 ACCESS Newswire · Jun 23, 2026

Cash Flow (USD)

Metric20212022202320242025
Operating Cash Flow$-2.0M$-4.0M$-6.0M$-7.0M$-9.0M
Investing Cash Flow$0$0$-2.0M$0$0
Financing Cash Flow$3.0M$8.0M$0$1.0M$0
Net Cash Flow$1.0M$10.0M$-9.0M$-2.0M$5.0M
Free Cash Flow$-2.0M$-4.0M$-6.0M$-7.0M$-9.0M

Valuation & Return Ratios

MetricValue
PEG Ratio—
EV / EBITDA—
FCF Yield-147.95%
Quick Ratio1.34
Interest Coverage—
Return 1Y-91.78%
Return 3Y-98.64%
Return 5Y—

Ownership

Insiders Held2.29%
Institutions Held6.44%
Institutions Float Held6.59%
Institutional HolderSharesReport Date
Vanguard Capital Management LLC55,5432026-03-31
Geode Capital Management, LLC48,2932026-03-31
J. Safra Sarasin Holding AG42,6002026-03-31
Vanguard Fiduciary Trust Co31,0712026-03-31
Schonfeld Strategic Advisors Llc24,4132026-03-31

Peer Comparison

TickerPriceChangeP/EMarket CapDiv Yield
ARTL $0.77 +1.96% -0.12 $1.80M 0.00%
CARMCarisma Therapeutics, Inc. $0.01 -5.17% 0.01 $230148 0.00%
GTBP $0.29 -4.65% -0.07 $3.12M 0.00%
LIPOLipella Pharmaceuticals Inc. $0.07 +0.00% -0.05 $300354 0.00%
MNDR $1.82 -16.51% -0.06 $44779 0.00%

About BIAF

BIAF is led by CEO Maria Zannes, publicly traded since 2022.

BIAF stock trades at $0.63 with a market capitalization of $2.84M. The stock is valued at a price-to-earnings (P/E) ratio of -0.19, price-to-book of 1.05, price-to-sales of 1.30. Over the past 52 weeks the stock has ranged between $0.63 and $13.80, and currently trades 95.4% below its 52-week high.

On profitability, BIAF generates a return on equity (ROE) of -214.29%, return on capital employed of -157.14%, an operating margin of -183.33%, a net profit margin of -2.81%.

Related Healthcare Stocks

LLY Drug Manufacturers - General $1185.71 -0.52% JNJ Drug Manufacturers - General $259.24 +0.88% ABBV Drug Manufacturers - General $246.04 +0.89% UNH Medical - Healthcare Plans $407.08 +0.77% MRK Drug Manufacturers - General $128.57 +0.16% NVS Drug Manufacturers - General $158.83 -0.64% NVO Biotechnology $51.58 +1.22% TMO Medical - Diagnostics & Research $594.00 +2.41% AMGN Drug Manufacturers - General $387.64 -1.39% ABT Medical - Devices $108.03 +0.70% GILD Drug Manufacturers - General $132.73 -1.18% PFE Drug Manufacturers - General $26.74 +2.06%

Popular Stocks

Apple (AAPL)Microsoft (MSFT)NVIDIA (NVDA)Alphabet (GOOGL)Amazon (AMZN)Meta (META)Tesla (TSLA)Broadcom (AVGO)JPMorgan (JPM)Visa (V)

Screens featuring this stock

High ROE Healthcare StocksLow P/E Healthcare StocksHigh Net Margin Healthcare StocksDividend Healthcare StocksLow Debt Healthcare StocksAll stock screens
Run Stock Screener Investing Guides